/ Research

DRIVING DISCOVERYACHIEVING BREAKTHROUGHS

Our passion is improving health.

Our passion to continuously improve health keeps us at the forefront of scientific research and development.

Behind each of our medicines and vaccines is a team of researchers who are leaders in their fields. People whose unwavering enthusiasm for finding new ways to prevent and treat disease is matched only by their unrelenting commitment to scientific excellence and patient safety.

It costs about €625 million and takes up to 10-12 years, to bring one medicine from discovery in a laboratory to the patient. The pharmaceutical industry invests around € 1 billion per year in research and development and carries out about 25 % of the global industrial research and development.

We are entering an exciting period with a strong product pipeline that targets a broad range of diseases. And we are looking forward to the next generation of health care by using new techniques and technologies.

Therapeutic Areas

We focus our research on several key therapeutic areas, including:

•Cardiovascular
•Diabetes and Obesity
•Bone, Respiratory, Immunology, and Dermatology
•Infectious Disease
•Oncology
•Neurosciences and Ophthalmology
•Women's Health and Endocrine

Products in the pipeline

From preclinical development to Phase III clinical trials, our passion for advancing health through science is evident in the breadth and depth of our pipeline.

Explore our pipeline

Forward-Looking Statement

Forward-Looking Statement of MSD & Co., Inc., Kenilworth, NJ, USA

This website of MSD & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.